USRE44872E1 - Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient - Google Patents

Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient Download PDF

Info

Publication number
USRE44872E1
USRE44872E1 US13/542,308 US200313542308A USRE44872E US RE44872 E1 USRE44872 E1 US RE44872E1 US 200313542308 A US200313542308 A US 200313542308A US RE44872 E USRE44872 E US RE44872E
Authority
US
United States
Prior art keywords
bladder
subject
active ingredient
overactive bladder
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US13/542,308
Inventor
Toshiyuki Takasu
Shuichi Sato
Masashi Ukai
Tatsuya Maruyama
Masayuki Shibasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE44872(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to US13/542,308 priority Critical patent/USRE44872E1/en
Application granted granted Critical
Publication of USRE44872E1 publication Critical patent/USRE44872E1/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Definitions

  • This invention relates to a remedy for overactive bladder comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof as an active ingredient.
  • Bladder of mammals is under a dual control of autonomic nerve and detrusor relaxes via an adrenaline ⁇ receptor by stimulation of sympathetic nerve upon urination while, upon excretion of urine, it contracts via a muscarine receptor by stimulation of parasympathetic nerve.
  • anticholinergic agents such as propiverine hydrochloride and oxybutynin hydrochloride have been mostly used at present.
  • Example 41 of a pamphlet of International Laid-Open WO 99/20607 that (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]-ethyl]acetic acid anilide dihydrochloride has both promotion action for insulin secretion and enhancing action for insulin sensitivity and further has anti-obese and anti-hyperlipemic actions whereby it is a useful compound for the treatment of diabetes mellitus but there is neither suggestion nor disclosure for the therapeutic use for overactive bladder (refer to Patent Document 1).
  • CGP-12,177A represented by the following chemical structural formula has a relaxation action for bladder (refer to Patent Document 2).
  • CGP-12,177A has been known as a selective drug having stimulating action to a ⁇ 3 -adrenaline receptor (refer to Non-Patent Documents 1 and 2)
  • R 1 is hydroxyl group, a lower alkyl group, an aralkoxy group, amino group, etc.;
  • R 2 is hydroxyl group or a lower alkyl group;
  • R 3 is hydrogen atom or halogen atom;
  • R 4 and R 5 each is hydrogen atom, halogen atom or a lower alkyl group; and
  • A is a lower alkylene group.
  • R 1 is hydrogen atom, a lower alkyl group or an aralkyl group
  • R 2 is hydrogen atom, a lower alkyl group or halogen atom
  • A is oxygen atom or imino group.
  • R 1 is hydroxyl group, etc.; one of R 2 and R 3 is hydrogen atom, halogen atom, etc. and another is hydrogen atom; and R 4 is halogen atom, etc.
  • Patent Document 1 Pamphlet of International Laid-Open WO 99/20607
  • Patent Document 2 Pamphlet of International Laid-Open WO 98/07445
  • Patent Document 3 Pamphlet of International Laid-Open WO 99/31045
  • Patent Document 4 Pamphlet of International Laid-Open WO 99/52856
  • Patent Document 5 Pamphlet of International Laid-Open WO 00/02846
  • Non-Patent Document 1 Drugs of the Future, 1993, volume 18, no. 6, page 542
  • Non-Patent Document 2 The American Society for Pharmacology and Experimental Therapeutics, 1993, volume 44, page 1100
  • the active ingredient of the present invention is useful as a remedy for diabetes mellitus and, as a result, they have found that the active ingredient of the present invention is useful as a remedy particularly for overactive bladder.
  • overactive bladder is defined as a disease by which urinary urgency is frequently resulted.
  • overactive bladder is sometimes accompanied by urinary frequency and urinary incontinence, it is not limited to the disease which is always accompanied by urinary frequency and urinary incontinence.
  • overactive bladder a patient is sensitive to the sense of wishing to urinate and frequently has a sense of wishing to urinate but, actually, he/she is able to hold his/her urine for a while.
  • QOL quality of life
  • Urinary frequency is a state where number of times of urination is more than the normal one and is said to be not less than about two times at night and not less than about 8 times during 24 hours.
  • urinary incontinence there is an involuntary leakage of urine and that is defined as a state where there is a problem socially or hygienically and is classified into stress urinary incontinence which occurs when abdominal pressure is applied such as cough and sneeze, urinary urge incontinence where a desire to urinate suddenly occurs and urine leaks before arriving at the toilet and urinary incontinence of a mixed type where both stress urinary incontinence and urinary urge incontinence are present.
  • the characteristic feature of the present invention is that the active ingredient of the present invention mitigates especially the frequent occurrence of urinary urgency of a patient and number of times of urination and state of urination are made into a more normal state.
  • overactive bladder in the present invention includes not only that as a result of benign prostatic hyperplasia but also that accompanied with urinary urgency, urinary incontinence and pollakiuria.
  • the active ingredient of the present invention is useful, in addition to treatment of diabetes, as an agent for prevention and treatment of other diseases where an improvement in symptom is able to be achieved by reducing the symptom of obesity and hyperlipemia such as arteriosclerosis, ischemic cardiac disease such as cardiac infarction and angina pectoris, brain artery sclerosis such as cerebral infarction, aneurysm, etc.
  • arteriosclerosis ischemic cardiac disease
  • angina pectoris ischemic cardiac disease
  • brain artery sclerosis such as cerebral infarction, aneurysm, etc.
  • the active ingredient of the present invention is useful as a remedy for overactive bladder.
  • Patent Document 2 use for overactive bladder is not mentioned as well.
  • CGP-12,177A has a relaxation action to bladder as a compound having a selective stimulating action to a ⁇ 3 -adrenaline receptor.
  • the active ingredient of the present invention has far stronger relaxation action for bladder.
  • Patent Document 2 there is no description for in vivo tests showing the usefulness for the treatment of overactive bladder such as “rat rhythmic bladder contraction measurement test” and “urination function measurement test on cyclophosphamide-induced overactive bladder model rat”.
  • Patent Documents 3 to 5 use for overactive bladder is not mentioned in Patent Documents 3 to 5 as well.
  • Compounds mentioned in Patent Documents 3 to 5 and the active ingredient of the present invention are different in their fundamental structures in such respects that the compounds mentioned in the documents always have a phenol ring but have no thiazole ring and also have no amide bond.
  • Patent Documents 3 to 5 there is no description for in vivo tests showing the usefulness for the treatment of over active bladder such as “rat rhythmic bladder contraction measurement test” and “urination function measurement test on cyclophosphamide-induced overactive bladder model rat”.
  • (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof is an active ingredient.
  • the characteristic feature of the present invention is that the active ingredient of the present invention has been found to be useful as a remedy for overactive bladder which is a new use.
  • the active ingredient of the present invention is a free substance having no salt.
  • it may form a salt with an acid and examples of the salt are acid addition salts with a mineral acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid and phosphoric acid and an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid and glutamic acid.
  • a mineral acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid and phosphoric acid
  • an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid,
  • the active ingredient of the present invention having a salt may be easily manufactured from a free substance by a common salt-forming reaction.
  • the active ingredient of the present invention further includes hydrate, solvate and polymorphism.
  • the active ingredient of the present invention still further includes pharmacologically acceptable prodrug.
  • a group for forming the prodrug that mentioned in Prog. Med. 5, 2157-2161 (1985) and “Iyakuhin no Kaihatsu” (Development of Drugs) (Hirokawa Shoten, 1990), volume 7, Molecule Design, 163-198 may be exemplified.
  • the drug containing the active ingredient of the present invention may be in any of forms of oral administration by tablets, pills, capsules, granules, diluted powder, etc. and parenteral administration by inhalant, etc.
  • a solid composition for oral administration tablets, diluted powder, granules, etc. are used.
  • one or more active ingredient(s) is/are mixed with at least one inert excipient such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone and magnesium metasilicate aluminate.
  • the composition may contain an inert additive such as lubricant (e.g., magnesium stearate), disintegrating agent (e.g., carboxymethyl starch sodium), solubilizing agent, etc. by a common method.
  • Tablets and pills may, if necessary, be coated with sugar coat or with an intragastric or enteric coating agent. Dose may be appropriately decided for each case taking symptom, age and sex of the subject to be administered, etc. into consideration. Usually, it is about 0.01 mg/kg to 100 mg/kg per day for an adult in the case of oral administration and is administered either at one time or by dividing into two to four.
  • the active ingredient of the present invention is able to be easily manufactured by a method mentioned in Patent Document 1 but, since method for the manufacture of a free substance which is preferred as the active ingredient of the present invention is not specifically mentioned therein, such a manufacturing method is shown in Manufacturing Examples. Route for the manufacture is illustrated as follows.
  • the organic layer was successively washed with 60 liters of 1M aqueous hydrochloric acid, 60 liters of 20% aqueous solution of potassium carbonate and water (60 liters, 60 liters) and concentrated in vacuo at 10 to 19° C.
  • the residue was dissolved in 35 liters of toluene with heating at 87° C., cooled and stirred at 20° C. throughout one night.
  • the resulting crystals were filtered and washed with 10 liters of toluene. This was dried in vacuo to give 7.66 kg of (R)-2-hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide as light yellow crystals.
  • EDC 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide monohydrochloride
  • the compound A which is the active ingredient of the present invention showed a strong relaxation action in antagonism test to contraction by carbachol and antagonism test to contraction by potassium chloride in an isolated rat bladder smooth muscle relaxation test.
  • the compound A showed a significantly strong relaxation action as compared with CGP-12,177A (control compound).
  • Relaxation rates to drug concentration of the compound A which is the active ingredient of the present invention and the control compound are shown in FIG. 1 (antagonism test to contraction by carbachol) and FIG. 2 (antagonism test to contraction by potassium chloride), respectively. Further, EC 50 and maximum relaxation rate of the test drug in the antagonism test to contraction by carbachol are shown in Table 1 while concentration comparison of the compound A expressing the maximum relaxation rate of CGP-12,177A is shown in Table 2. The compound A showed an action strength of 270-fold as compared with the CGP-12,177A (control compound).
  • EC 50 and maximum relaxation rate of the test drug in the antagonism test to contraction by potassium chloride are shown in Table 3 while concentration comparison of the compound A expressing the maximum relaxation rate of CGP-12,177A is shown in Table 4.
  • the compound A showed an action strength of 383-fold as compared with the CGP-12,177A (control compound).
  • Female rats (225 to 290 g) of Wistar strain was used for the test. Under anesthetization with urethane, right and left ureters were ligated and cut and, after that, a polyethylene cannula was inserted from external urinary meatus and fixed. One end of the fixed cannula was connected to a pressure transducer via a three-way cock and pressure in the bladder was measured. Another end thereof was connected to a syringe pump and a physiological saline solution was continuously infused at a constant rate into bladder whereupon rhythmic bladder contraction was induced. The continuous infusion of a physiological saline solution was stopped after a rhythmic bladder contraction was noted. After the rhythmic bladder contraction was stabilized, drug or vehicle was administered from a catheter for administration of drug inserted into femoral vein.
  • the compound A was intravenously administered in increased doses where the ratio was 3 (0.03, 0.1, 0.3, 1 and 3 mg/kg).
  • a group to which vehicle was administered was used as a control group.
  • a suppressive effect for contraction frequency by the compound A is presumed to be due to an increase in bladder volume by stimulation of the compound A for a ⁇ 3 receptor existing in the bladder. It has been believed that an increase in functional bladder volume showing the urine volume which is able to be stored in the bladder is clinically useful for the treatment of patients suffering from overactive bladder and, therefore, the compound A is believed to be clinically effective as a remedy for overactive bladder.
  • Overactive bladder model rats induced by cyclophosphamide were prepared by referring to British Journal of Pharmacology, 2000, volume 130, page 331 and the following test was conducted.
  • mice Female rats (220 to 230 g) of Wistar strain were used for the test. Under anesthetization with pentobarbital sodium, a catheter for infusion of physiological saline solution and for measurement of pressure in bladder was inserted into bladder from the top of the bladder and fixed while a catheter for administration of a drug was inserted into carotid vein and fixed. Cyclophosphamide (CYP) was administered into abdominal cavity and, after being recovered, the rats were returned to a feeding cage. On the next day of the operation, one end of the catheter inserted into bladder of the rat was connected to a syringe pump via a three-way cock and a physiological saline solution was continuously infused whereby micturition reflex was induced. Another end was connected to a pressure transducer and pressure in the bladder was measured. After the micturition reflex was stabilized, 1 mg/kg of the compound A was administered from a catheter for administration of drug which was inserted into carotid vein.
  • Cyclophosphamide CY
  • the active ingredient of the present invention shows a strong bladder relaxation action in “isolated rat bladder smooth muscle relaxation test”, decreases the contraction frequency of rhythmic bladder contraction on a dose-depending manner in “rat rhythmic bladder contraction measurement test” and prolongs the micturition interval in “micturition function measurement test on cyclophosphamide-induced overactive bladder model rat” whereby it is clinically useful as a remedy for overactive bladder.
  • overactive bladder as a result of benign prostatic hyperplasia, it is also able to be used as a remedy for overactive bladder accompanied with urinary urgency, urinary incontinence and pollakiuria.
  • the active ingredient of the present invention (200.0 g) and 399.0 g of lactose were mixed in a polyethylene bag.
  • the mixture was mixed and disintegrated in a sample mill (manufactured by Hosokawa Micron).
  • the disintegrated mixture 450.0 g) and 60.1 g of corn starch were uniformly mixed in a fluidized granulation coating apparatus (manufactured by Ogawara Seisakusho).
  • a 10% hydroxypropyl cellulose solution (192 g) was sprayed thereon to granulate.
  • (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof which is an active ingredient of the present invention showed a significantly strong relaxation action as compared with the control compound in “isolated rat bladder smooth muscle relaxation test”. Further, it decreased the contraction frequency of rhythmic bladder contraction on a dose-dependent manner in “rat rhythmic bladder contraction measurement test”. Still further, it prolonged the micturition interval of cyclophosphamide-induced overactive bladder model rat in “micturition function measurement test on cyclophosphamide-induced overactive bladder model rat”.
  • (R)-2-(2-Aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof which is an active ingredient of the present invention is able to be used as a remedy for overactive bladder.
  • overactive bladder as a result of benign prostatic hyperplasia, it is also able to be used as a remedy for overactive bladder accompanied with urinary urgency, urinary incontinence and pollakiuria.
  • FIG. 1 Effects of the compound A and the control compound to isolated rat bladder smooth muscle relaxation test (antagonism test to contraction by carbachol)
  • FIG. 2 Effects of the compound A and the control compound to isolated rat bladder smooth muscle relaxation test (antagonism test to contraction by potassium chloride)
  • FIG. 3 Effect of the compound A to rat rhythmic bladder contraction (effect to contraction frequency ( ⁇ : p ⁇ 0.05))
  • FIG. 4 Effect of the compound A to rat rhythmic bladder contraction (effect to contraction pressure)
  • FIG. 5 Effect of the compound A to micturition function of cyclophosphamide-induced overactive bladder model rat (showing the urination interval after administration of a drug where the urination interval before administration of the drug was defined as 100%)

Abstract

(R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or its salt shows a potent bladder relaxation effect in “isolated rat bladder smooth muscle relaxation test”, dose-dependently lowers the contraction frequency of rhythmic bladder contractions in “rat rhythmic bladder contraction measurement test” and, moreover, prolongs the urination intervals in “urination functions measurement test on cyclophosphamide-induced overactive bladder model rat”. Owing to these effects, the above compound is useful as a remedy for ovaractive bladder.

Description

TECHNICAL FIELD
This invention relates to a remedy for overactive bladder comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof as an active ingredient.
BACKGROUND
Bladder of mammals is under a dual control of autonomic nerve and detrusor relaxes via an adrenaline β receptor by stimulation of sympathetic nerve upon urination while, upon excretion of urine, it contracts via a muscarine receptor by stimulation of parasympathetic nerve. As a remedy for overactive bladder resulted when the dual control as such is unbalanced, anticholinergic agents such as propiverine hydrochloride and oxybutynin hydrochloride have been mostly used at present. However, there are intractable cases showing resistance to such compounds and there are side effects caused by anticholinergic agents such as urinary dysfunction and dry mouth and, therefore, it is the current status that satisfactory clinical results are not always achieved.
Further, as a result of increase in population of aged people in recent years, numbers of patients suffering from overactive bladder are increasing year by year and, in view of QOL (quality of life) of patients, there has been a brisk demand for the development of new drugs.
The present inventors reported in Example 41 of a pamphlet of International Laid-Open WO 99/20607 that (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]-ethyl]acetic acid anilide dihydrochloride has both promotion action for insulin secretion and enhancing action for insulin sensitivity and further has anti-obese and anti-hyperlipemic actions whereby it is a useful compound for the treatment of diabetes mellitus but there is neither suggestion nor disclosure for the therapeutic use for overactive bladder (refer to Patent Document 1).
Figure USRE044872-20140429-C00001
In the meanwhile, in a pamphlet of International Laid-Open WO 98/07445, as an agent for prevention and treatment of urinary frequency and urinary incontinence containing a drug having stimulating action to a β3-adrenaline receptor as an active ingredient, there is mentioned that CGP-12,177A represented by the following chemical structural formula has a relaxation action for bladder (refer to Patent Document 2). CGP-12,177A has been known as a selective drug having stimulating action to a β3-adrenaline receptor (refer to Non-Patent Documents 1 and 2)
Figure USRE044872-20140429-C00002
In a pamphlet of International Laid-Open WO 99/31045, compounds represented by the following formula are mentioned as having a stimulating action to a β3-adrenaline receptor and as an agent for prevention or treatment of diseases caused by obesity, hyperglycemia and acceleration of movement of intestinal tract and diseases caused by urinary frequency or urinary incontinence, melancholia, biliary calculus or acceleration of bile duct movement (refer to Patent Document 3).
Figure USRE044872-20140429-C00003
(In the formula, R1 is hydroxyl group, a lower alkyl group, an aralkoxy group, amino group, etc.; R2 is hydroxyl group or a lower alkyl group; R3 is hydrogen atom or halogen atom; R4 and R5 each is hydrogen atom, halogen atom or a lower alkyl group; and A is a lower alkylene group.)
In a pamphlet of International Laid-Open WO 99/52856, compounds represented by the following formula are mentioned as having a stimulating action to a β3-adrenaline receptor and as an agent for prevention or treatment of diseases caused by obesity, hyperglycemia and acceleration of movement of intestinal tract and diseases caused by urinary frequency or urinary incontinence, melancholia, biliary calculus or acceleration of bile duct movement (refer to Patent Document 4).
Figure USRE044872-20140429-C00004
(In the formula, R1 is hydrogen atom, a lower alkyl group or an aralkyl group; R2 is hydrogen atom, a lower alkyl group or halogen atom; and A is oxygen atom or imino group.)
In a pamphlet of International Laid-Open WO 00/02846, compounds represented by the following formula are mentioned as having a stimulating action to a β3-adrenaline receptor and as an agent for prevention or treatment of diseases caused by obesity, hyperglycemia and acceleration of movement of intestinal tract and diseases caused by urinary frequency or urinary incontinence, melancholia, biliary calculus or acceleration of bile duct movement (refer to Patent Document 5).
Figure USRE044872-20140429-C00005
(In the formula, R1 is hydroxyl group, etc.; one of R2 and R3 is hydrogen atom, halogen atom, etc. and another is hydrogen atom; and R4 is halogen atom, etc.)
Patent Document 1: Pamphlet of International Laid-Open WO 99/20607
Patent Document 2: Pamphlet of International Laid-Open WO 98/07445
Patent Document 3: Pamphlet of International Laid-Open WO 99/31045
Patent Document 4: Pamphlet of International Laid-Open WO 99/52856
Patent Document 5: Pamphlet of International Laid-Open WO 00/02846
Non-Patent Document 1: Drugs of the Future, 1993, volume 18, no. 6, page 542
Non-Patent Document 2: The American Society for Pharmacology and Experimental Therapeutics, 1993, volume 44, page 1100
DISCLOSURE OF THE INVENTION
The present inventors have carried out intensive studies for finding new pharmacological effects of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]-ethyl]acetic acid anilide or a salt thereof (hereinafter, referred to as “the active ingredient of the present invention”) which is useful as a remedy for diabetes mellitus and, as a result, they have found that the active ingredient of the present invention is useful as a remedy particularly for overactive bladder. In the present invention, overactive bladder is defined as a disease by which urinary urgency is frequently resulted. Although benign prostatic hyperplasia is exemplified as one of the causes for overactive bladder, there are many cases where the cause is ambiguous and they are called idiopathic overactive bladder. Although overactive bladder is sometimes accompanied by urinary frequency and urinary incontinence, it is not limited to the disease which is always accompanied by urinary frequency and urinary incontinence. Thus, in the case of mild overactive bladder, a patient is sensitive to the sense of wishing to urinate and frequently has a sense of wishing to urinate but, actually, he/she is able to hold his/her urine for a while. However, even in the case of a mild overactive bladder, its improvement has been strongly demanded in view of QOL (quality of life) of a patient. On the other hand, a severe overactive bladder is sometimes accompanied by urinary frequency and urinary incontinence. Urinary frequency is a state where number of times of urination is more than the normal one and is said to be not less than about two times at night and not less than about 8 times during 24 hours. In urinary incontinence, there is an involuntary leakage of urine and that is defined as a state where there is a problem socially or hygienically and is classified into stress urinary incontinence which occurs when abdominal pressure is applied such as cough and sneeze, urinary urge incontinence where a desire to urinate suddenly occurs and urine leaks before arriving at the toilet and urinary incontinence of a mixed type where both stress urinary incontinence and urinary urge incontinence are present.
The characteristic feature of the present invention is that the active ingredient of the present invention mitigates especially the frequent occurrence of urinary urgency of a patient and number of times of urination and state of urination are made into a more normal state. It goes without saying that overactive bladder in the present invention includes not only that as a result of benign prostatic hyperplasia but also that accompanied with urinary urgency, urinary incontinence and pollakiuria.
In Patent Document 1, the active ingredient of the present invention is useful, in addition to treatment of diabetes, as an agent for prevention and treatment of other diseases where an improvement in symptom is able to be achieved by reducing the symptom of obesity and hyperlipemia such as arteriosclerosis, ischemic cardiac disease such as cardiac infarction and angina pectoris, brain artery sclerosis such as cerebral infarction, aneurysm, etc. However, there is neither description nor suggestion at all to the effect that the active ingredient of the present invention is useful as a remedy for overactive bladder.
In Patent Document 2, use for overactive bladder is not mentioned as well. In Patent Document 2, there is a description that only CGP-12,177A has a relaxation action to bladder as a compound having a selective stimulating action to a β3-adrenaline receptor. However, as compared with CGP-12,177A, the active ingredient of the present invention has far stronger relaxation action for bladder. In addition, in Patent Document 2, there is no description for in vivo tests showing the usefulness for the treatment of overactive bladder such as “rat rhythmic bladder contraction measurement test” and “urination function measurement test on cyclophosphamide-induced overactive bladder model rat”.
Further, use for overactive bladder is not mentioned in Patent Documents 3 to 5 as well. Compounds mentioned in Patent Documents 3 to 5 and the active ingredient of the present invention are different in their fundamental structures in such respects that the compounds mentioned in the documents always have a phenol ring but have no thiazole ring and also have no amide bond. In addition, in Patent Documents 3 to 5, there is no description for in vivo tests showing the usefulness for the treatment of over active bladder such as “rat rhythmic bladder contraction measurement test” and “urination function measurement test on cyclophosphamide-induced overactive bladder model rat”.
The present invention will now be illustrated in detail as hereunder.
In the present invention, (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof is an active ingredient. The characteristic feature of the present invention is that the active ingredient of the present invention has been found to be useful as a remedy for overactive bladder which is a new use.
It is particularly preferred that the active ingredient of the present invention is a free substance having no salt. However, it may form a salt with an acid and examples of the salt are acid addition salts with a mineral acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid and phosphoric acid and an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid and glutamic acid. The active ingredient of the present invention having a salt may be easily manufactured from a free substance by a common salt-forming reaction. The active ingredient of the present invention further includes hydrate, solvate and polymorphism. The active ingredient of the present invention still further includes pharmacologically acceptable prodrug. With regard to a group for forming the prodrug, that mentioned in Prog. Med. 5, 2157-2161 (1985) and “Iyakuhin no Kaihatsu” (Development of Drugs) (Hirokawa Shoten, 1990), volume 7, Molecule Design, 163-198 may be exemplified.
The drug containing the active ingredient of the present invention may be in any of forms of oral administration by tablets, pills, capsules, granules, diluted powder, etc. and parenteral administration by inhalant, etc. As to a solid composition for oral administration, tablets, diluted powder, granules, etc. are used. In the solid composition as such, one or more active ingredient(s) is/are mixed with at least one inert excipient such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone and magnesium metasilicate aluminate. The composition may contain an inert additive such as lubricant (e.g., magnesium stearate), disintegrating agent (e.g., carboxymethyl starch sodium), solubilizing agent, etc. by a common method. Tablets and pills may, if necessary, be coated with sugar coat or with an intragastric or enteric coating agent. Dose may be appropriately decided for each case taking symptom, age and sex of the subject to be administered, etc. into consideration. Usually, it is about 0.01 mg/kg to 100 mg/kg per day for an adult in the case of oral administration and is administered either at one time or by dividing into two to four.
The active ingredient of the present invention is able to be easily manufactured by a method mentioned in Patent Document 1 but, since method for the manufacture of a free substance which is preferred as the active ingredient of the present invention is not specifically mentioned therein, such a manufacturing method is shown in Manufacturing Examples. Route for the manufacture is illustrated as follows.
Figure USRE044872-20140429-C00006
MANUFACTURING EXAMPLES Manufacturing Method for the Active Ingredient of the Present Invention
Step 1
To a mixture of 5.90 kg of 4-nitrophenylethylamine monohydrochloride, 4.43 kg of (R)-mandelic acid, 2.94 kg of triethylamine and 22 liters of N, N-dimethylformamide were added 3.93 kg of hydroxybenztriazole and 5.58 kg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide monohydrochloride (EDC) followed by stirring at about room temperature for 2 hours. EDC (0.28 kg) was further added thereto and the mixture was stirred at about room temperature throughout one night. The reaction solution was diluted with 110 liters of water and extracted with ethyl acetate (60 liters, 30 liters). The organic layer was successively washed with 60 liters of 1M aqueous hydrochloric acid, 60 liters of 20% aqueous solution of potassium carbonate and water (60 liters, 60 liters) and concentrated in vacuo at 10 to 19° C. The residue was dissolved in 35 liters of toluene with heating at 87° C., cooled and stirred at 20° C. throughout one night. The resulting crystals were filtered and washed with 10 liters of toluene. This was dried in vacuo to give 7.66 kg of (R)-2-hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide as light yellow crystals.
1H-NMR (DMSO-d6, 400 MHz) δ (ppm)=2.87 (2H, t, J=7.2 Hz), 3.30-3.46 (2H, m), 4.85 (1H, d, J=4.8 Hz), 6.12 (1H, d, J=4.8 Hz), 7.20-7.33 (5H, m), 7.40 (2H, d, J=8.0 Hz), 8.04-8.12 (3H, m). FAB-MS m/z: 301 (M+H)+.
Step 2
A mixture of 7.51 kg of (R)-2-hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide, 23 liters of 1,3-dimethyl-2-imidazolidinone and 23 liters of tetrahydrofuran was cooled at −18° C. and 49.4 kg of 1M boran-tetrahydrofuran solution was dropped there into at not higher than −7° C. After that, temperature of the mixture was raised to 70° C. followed by stirring for 5 hours. The reaction mixture was cooled at −12° C. and 2.9 kg of methanol and 5.9 kg of concentrated hydrochloric acid were added thereto at not higher than 5° C. After stirring at 68° C. for 1 hour, the mixture was concentrated in vacuo until the amount became 50 liters. A 30% aqueous solution (60 kg) of K2CO3 and 6 liters of water were added thereto followed by extracting with 75 liters of ethyl acetate. The organic layer was washed with 75 liters of water and concentrated in vacuo. Isopropanol (75 liters) was added to the residue, the mixture was dissolved at 40° C. and 2.46 kg of concentrated hydrochloric acid was added to crystallize followed by stirring at 23° C. throughout one night. The crystals were filtered and washed with 38 liters of isopropanol. They were dried in vacuo to give 7.29 kg of (R)-2-[[2-(4-nitrophenyl)ethyl]amino]-1-phenylethanol monohydrochloride.
1H-NMR (DMSO-d6, 400 MHz) δ (ppm)=3.00-3.08 (1H, m), 3.15-3.30 (5H, m), 5.00-5.05 (1H, m), 6.23 (1H, d, J=4.0 Hz), 7.29-7.35 (1H, m), 7.36-7.43 (4H. m), 7.57 (2H, d, J=8.4 Hz), 8.21 (2H, d, J=8.4 Hz), 9.12 (2H, br). FAB-MS m/z: 287 (M+H)+.
Step 3
A mixture of 11.0 kg of (R)-2-[[2-(4-nitrophenyl)ethyl]amino]-1-phenylethanol monohydrochloride, 110 liters of methanol and 1.20 kg of wet 10% palladium-carbon (wetting rate: 54.2%) was stirred in a hydrogen atmosphere until absorption of hydrogen stopped. The reaction solution was filtered and the filtrate was concentrated in vacuo. Methanol (40 liters) was added to the residue to dissolve at 40° C. and crystallization was conducted by addition of 220 liters of diisopropyl ether thereto followed by stirring at 20° C. throughout one night. The crystals were filtered and washed with 30 liters of diisopropyl ether. They were dried in vacuo to give 9.43 kg of (R)-2-[[2-(4-aminophenyl)ethyl]amino]-1-phenylethanol monohydrochloride.
1H-NMR (DMSO-d6, 400 MHz) δ (ppm)=2.76-2.90 (2H, m), 2.95-3.16 (4H, m), 4.95-5.11 (3H, m), 6.20 (1H, d, J=4.0 Hz), 6.53 (2H, d, J=8.4 Hz), 6.89 (2H, d, J=8.4 Hz), 7.28-7.43 (5H, m), 8.97 (1H, br), 9.29 (1H, br). FAB-MS m/z: 257 (M+H)+.
Step 4
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide monohydrochloride (EDC) (5.76 g) was added to a mixture of 8.00 g of (R)-2-[[2-(4-aminophenyl)ethyl]amino]-1-phenylethanol monohydrochloride, 4.32 g of 2-aminothiazol-4-yl acetic acid, 2.64 g of concentrated hydrochloric acid and 120 ml of water at room temperature followed by stirring for 1 hour. A mixed solution of 2.40 g of sodium hydroxide and 40 ml of water was dropped into the reaction solution to crystallize. The resulting crystals were filtered, washed with water and dried in vacuo to give 9.93 g of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]-ethyl]acetic acid anilide (hereinafter, referred to as “compound A”).
1H-NMR (DMSO-d6, 500 MHz) δ (ppm)=1.60 (1H, s), 2.59-2.66 (4H, m), 2.68-2.80 (2H, m), 3.45 (2H, s), 4.59 (1H, br), 5.21 (1H, br), 6.30 (1H, s), 6.89 (2H, s), 7.11 (2H, d, J=8.5 Hz), 7.19-7.23 (1H, m), 7.27-7.33 (4H, m), 7.49 (2H, d, J=8.5 Hz), 9.99 (1H, s). FAB-MS m/z: 397 (M+H)+.
BEST MODE FOR CARRYING OUT THE INVENTION
The present invention will now be specifically illustrated by way of the following Examples but the present invention is not limited to the content thereof.
Example 1 Isolated Rat Bladder Smooth Muscle Relaxation Test
Test Method
The test was conducted by referring to The Journal of Urology, 1999, volume 161, page 680.
Male rats of Wistar strain of 10 to 11 weeks age were sacrificed by depletion, whole bladder was isolated by laparotomy and bladder sections each being in a size of about 3×10 mm were prepared in a nutrient solution which was well oxygenated with 95% O2 and 5% CO2 (Krebs-Henseleit solution (118.4 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4; 1.2 mM MgSO4, 2.5 mM CaCl2, 25.0 mM NaHCO3 and 11.1 mM glucose)). The section was hung in a Magnus tube in which a nutrient solution (Krebs-Henseleit solution) of 37° C. into which 95% O2 and 5% CO2 were aerated, stabilized for 30 to 60 minutes with a load of 1 g and 10−6 M carbachol (CCh) or 40 mM potassium chloride (KCl) was repeatedly applied thereto whereupon it was confirmed that reactivity to CCh or KCl became almost constant. After contraction by 10−6 M CCh or 40 mM KCl was induced and the generated tension was stabilized, a test drug (compound A or CGP-12,177A) was cumulatively administered in 10-fold ratio with intervals of about 10 minutes and the relaxation reaction was observed. After completion of observation of relaxation reaction at maximum concentration of the test drug, 10−4 M papaverine was added to induce the maximum relaxation and a relaxation rate was calculated where the relaxation reaction was defined as 100%.
Results
As a result of the above test, the compound A which is the active ingredient of the present invention showed a strong relaxation action in antagonism test to contraction by carbachol and antagonism test to contraction by potassium chloride in an isolated rat bladder smooth muscle relaxation test. In addition, the compound A showed a significantly strong relaxation action as compared with CGP-12,177A (control compound).
Relaxation rates to drug concentration of the compound A which is the active ingredient of the present invention and the control compound are shown in FIG. 1 (antagonism test to contraction by carbachol) and FIG. 2 (antagonism test to contraction by potassium chloride), respectively. Further, EC50 and maximum relaxation rate of the test drug in the antagonism test to contraction by carbachol are shown in Table 1 while concentration comparison of the compound A expressing the maximum relaxation rate of CGP-12,177A is shown in Table 2. The compound A showed an action strength of 270-fold as compared with the CGP-12,177A (control compound). Similarly, EC50 and maximum relaxation rate of the test drug in the antagonism test to contraction by potassium chloride are shown in Table 3 while concentration comparison of the compound A expressing the maximum relaxation rate of CGP-12,177A is shown in Table 4. The compound A showed an action strength of 383-fold as compared with the CGP-12,177A (control compound).
TABLE 1
EC50 and maximum relaxation rate of the test drug
in the antagonism test to contraction by carbachol
Test Drug EC50 (M) Maximum Relaxation Rate (%)
Compound A 5.2 × 10−6 94.0
(Active Ingredient of
the Present Invention)
CGP-12, 177A >10−4 15.7
(Control Compound)
TABLE 2
Concentration comparison of the compound A expressing
the maximum relaxation rate of CGP-12, 177A in antagonism
test to contraction by carbachol
Comparison of Action
Test Drug Concentration (M) Strength*
Compound A 3.7 × 10−7 270
(Active Ingredient of
the Present Invention)
CGP-12, 177A 10−4 1
(Control Compound)
*Compared in the concentration where the compound showed a relaxation rate of 15.7%
TABLE 3
EC50 and maximum relaxation rate of the test drug in the
antagonism test to contraction by potassium chloride
Test Drug EC50 (M) Maximum Relaxation Rate (%)
Compound A 1.1 × 10−5 69.1
(Active Ingredient of
the Present Invention)
CGP-12, 177A >10−4 17.4
(Control Compound)
TABLE 4
Concentration comparison of the compound A expressing
the maximum relaxation rate of CGP-12, 177A in antagonism
test to contraction by potassium chloride
Comparison of Action
Test Drug Concentration (M) Strength*
Compound A 2.6 × 10−7 383
(Active Ingredient of
the Present Invention)
CGP-12, 177A 10−4 1
(Control Compound)
*Compared in the concentration where the compound showed a relaxation rate of 17.4%
Example 2 Rat Rhythmic Bladder Contraction Measurement Test
Test Method
The test was conducted by referring to European Journal of Pharmacology, 2000, volume 407, page 175.
1. Measuring Method
Female rats (225 to 290 g) of Wistar strain was used for the test. Under anesthetization with urethane, right and left ureters were ligated and cut and, after that, a polyethylene cannula was inserted from external urinary meatus and fixed. One end of the fixed cannula was connected to a pressure transducer via a three-way cock and pressure in the bladder was measured. Another end thereof was connected to a syringe pump and a physiological saline solution was continuously infused at a constant rate into bladder whereupon rhythmic bladder contraction was induced. The continuous infusion of a physiological saline solution was stopped after a rhythmic bladder contraction was noted. After the rhythmic bladder contraction was stabilized, drug or vehicle was administered from a catheter for administration of drug inserted into femoral vein.
2. Drug
The compound A was intravenously administered in increased doses where the ratio was 3 (0.03, 0.1, 0.3, 1 and 3 mg/kg). A group to which vehicle was administered was used as a control group.
3. Evaluated Items and Statistical Analysis
Parameters for evaluation were number of times and contraction pressure of bladder contraction during 10 minutes from 5 to 15 minutes after the administration of the drug and each group was conducted in n=5. The result is shown in terms of mean value ± standard error and Student t-test was conducted for comparison between the two groups.
Results
By intravenous administration of the compound A, contraction frequency of rhythmic bladder contraction decreased on a dose-dependent manner (FIG. 3). An action of decreasing the contraction frequency by intravenous injection (i.v.) of 3 mg/kg of the compound A was significant as compared with the control group. On the other hand, the compound A did not affect the contraction pressure until intravenous administration of 3 mg/kg (FIG. 4). The fact of no influence on the contraction pressure is a preferred property from the viewpoint that urinary retention is not induced or that residual urine is not resulted upon urination.
A suppressive effect for contraction frequency by the compound A is presumed to be due to an increase in bladder volume by stimulation of the compound A for a β3 receptor existing in the bladder. It has been believed that an increase in functional bladder volume showing the urine volume which is able to be stored in the bladder is clinically useful for the treatment of patients suffering from overactive bladder and, therefore, the compound A is believed to be clinically effective as a remedy for overactive bladder.
Example 3 Test for Measurement of Urination Function of Model Rat Suffering from Overactive Bladder Induced by Cyclophosphamide
Overactive bladder model rats induced by cyclophosphamide were prepared by referring to British Journal of Pharmacology, 2000, volume 130, page 331 and the following test was conducted.
Test Method
1. Measuring Method
Female rats (220 to 230 g) of Wistar strain were used for the test. Under anesthetization with pentobarbital sodium, a catheter for infusion of physiological saline solution and for measurement of pressure in bladder was inserted into bladder from the top of the bladder and fixed while a catheter for administration of a drug was inserted into carotid vein and fixed. Cyclophosphamide (CYP) was administered into abdominal cavity and, after being recovered, the rats were returned to a feeding cage. On the next day of the operation, one end of the catheter inserted into bladder of the rat was connected to a syringe pump via a three-way cock and a physiological saline solution was continuously infused whereby micturition reflex was induced. Another end was connected to a pressure transducer and pressure in the bladder was measured. After the micturition reflex was stabilized, 1 mg/kg of the compound A was administered from a catheter for administration of drug which was inserted into carotid vein.
2. Evaluated Items and Statistical Analysis
Parameter for the evaluation was an average interval for urination from administration of the drug until 30 minutes thereafter. The result was shown in terms of an average urination interval after administration of the drug to the average urination interval before administration of the drug where an average urination interval during 30 minutes before administration of the drug was defined 100% and was shown in a mean value of n=3.
Results
As a result of intravenous administration of the compound A (1 mg/kg), micturition interval of overactive bladder model rats induced by cyclophosphamide was elongated to an extent of 17.3% (FIG. 5). From such a fact, the compound A which prolongs the micturition interval of the present model rats is believed to be clinically effective as a remedy for overactive bladder.
Thus, the active ingredient of the present invention shows a strong bladder relaxation action in “isolated rat bladder smooth muscle relaxation test”, decreases the contraction frequency of rhythmic bladder contraction on a dose-depending manner in “rat rhythmic bladder contraction measurement test” and prolongs the micturition interval in “micturition function measurement test on cyclophosphamide-induced overactive bladder model rat” whereby it is clinically useful as a remedy for overactive bladder. In addition to overactive bladder as a result of benign prostatic hyperplasia, it is also able to be used as a remedy for overactive bladder accompanied with urinary urgency, urinary incontinence and pollakiuria.
Example 4 Formulation Example
Formulation Example for Oral Agent
TABLE 5
Composition
Tablet
Active ingredient of the present invention 100.0 mg
Lactose 199.5 mg
Corn starch 40.0 mg
Hydroxypropyl cellulose 9.0 mg
Magnesium stearate 1.5 mg
Subtotal 350 mg
Coat
Hydroxypropyl methyl cellulose 2910 8.7 mg
Polyethylene glycol 6000 1.2 mg
Titanium oxide 4.8 mg
Talc 0.3 mg
Subtotal 15 mg
Grand total 365 mg

100-mg Tablet
The active ingredient of the present invention (200.0 g) and 399.0 g of lactose were mixed in a polyethylene bag. The mixture was mixed and disintegrated in a sample mill (manufactured by Hosokawa Micron). The disintegrated mixture (450.0 g) and 60.1 g of corn starch were uniformly mixed in a fluidized granulation coating apparatus (manufactured by Ogawara Seisakusho). A 10% hydroxypropyl cellulose solution (192 g) was sprayed thereon to granulate. After being dried, the above was passed through a sieve of 20 meshes, 2.3 g of magnesium stearate was added thereto and the mixture was made into tablets each comprising 350 mg by a rotary tabletting machine (manufactured by Hata Tekkosho) using a pounder of c/9.0 mm×10.8 R. The tablets were sprayed with 150 g of a coating solution containing 8.7 g of hydroxypropyl methyl cellulose, 1.2 g of polyethylene glycol 6000, 4.8 g of titanium oxide and 0.3 g of talc in a coating apparatus (manufactured by Freund Sangyo) to give film-coated tablets each being coated with 15 mg.
INDUSTRIAL APPLICABILITY
As mentioned hereinabove, (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof which is an active ingredient of the present invention showed a significantly strong relaxation action as compared with the control compound in “isolated rat bladder smooth muscle relaxation test”. Further, it decreased the contraction frequency of rhythmic bladder contraction on a dose-dependent manner in “rat rhythmic bladder contraction measurement test”. Still further, it prolonged the micturition interval of cyclophosphamide-induced overactive bladder model rat in “micturition function measurement test on cyclophosphamide-induced overactive bladder model rat”.
Accordingly, (R)-2-(2-Aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof which is an active ingredient of the present invention is able to be used as a remedy for overactive bladder. In addition to overactive bladder as a result of benign prostatic hyperplasia, it is also able to be used as a remedy for overactive bladder accompanied with urinary urgency, urinary incontinence and pollakiuria.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1: Effects of the compound A and the control compound to isolated rat bladder smooth muscle relaxation test (antagonism test to contraction by carbachol)
FIG. 2: Effects of the compound A and the control compound to isolated rat bladder smooth muscle relaxation test (antagonism test to contraction by potassium chloride)
FIG. 3: Effect of the compound A to rat rhythmic bladder contraction (effect to contraction frequency (★: p<0.05))
FIG. 4: Effect of the compound A to rat rhythmic bladder contraction (effect to contraction pressure)
FIG. 5: Effect of the compound A to micturition function of cyclophosphamide-induced overactive bladder model rat (showing the urination interval after administration of a drug where the urination interval before administration of the drug was defined as 100%)

Claims (14)

The invention claimed is:
1. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof as an active ingredient, wherein the subject is not suffering from diabetes.
2. The method according to claim 1, wherein the overactive bladder is a result of benign prostatic hyperplasia.
3. The method according to claim 1, wherein the subject has urinary urgency.
4. The method according to claim 1, wherein the subject has urinary urge incontinence.
5. The method according to claim 1, wherein the subject has pollakiuria.
6. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, in its free base form, as an active ingredient, wherein the subject is not suffering from diabetes.
7. The method according to claim 6, wherein the overactive bladder is a result of benign prostatic hyperplasia.
8. The method according to claim 6, wherein the subject has urinary urgency.
9. The method according to claim 6, wherein the subject has urinary urge incontinence.
10. The method according to claim 6, wherein the subject has pollakiuria.
11. The method according to claim 1, wherein the subject is human.
12. The method according to claim 6, wherein the subject is human.
13. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof as an active ingredient, wherein when the subject is not an adult, the subject is not suffering from diabetes.
14. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, in its free base form, as an active ingredient, wherein when the subject is not an adult, the subject is not suffering from diabetes.
US13/542,308 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient Expired - Lifetime USRE44872E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/542,308 USRE44872E1 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07
JP2002-323792 2002-11-07
US13/542,308 USRE44872E1 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
PCT/JP2003/014065 WO2004041276A1 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US10/534,290 US20060115540A1 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient

Publications (1)

Publication Number Publication Date
USRE44872E1 true USRE44872E1 (en) 2014-04-29

Family

ID=32310425

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/542,308 Expired - Lifetime USRE44872E1 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US10/534,290 Granted US20060115540A1 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US10/534,290 Ceased US7750029B2 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US12/333,357 Abandoned US20090093529A1 (en) 2002-11-07 2008-12-12 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US13/117,638 Expired - Lifetime US8835474B2 (en) 2002-11-07 2011-05-27 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient

Family Applications After (4)

Application Number Title Priority Date Filing Date
US10/534,290 Granted US20060115540A1 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US10/534,290 Ceased US7750029B2 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US12/333,357 Abandoned US20090093529A1 (en) 2002-11-07 2008-12-12 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US13/117,638 Expired - Lifetime US8835474B2 (en) 2002-11-07 2011-05-27 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient

Country Status (28)

Country Link
US (5) USRE44872E1 (en)
EP (1) EP1559427B1 (en)
JP (1) JP3815496B2 (en)
KR (1) KR100967070B1 (en)
CN (1) CN100406011C (en)
AT (1) ATE500827T1 (en)
AU (1) AU2003284700B2 (en)
BE (1) BE2013C040I2 (en)
BR (1) BR0316080A (en)
CA (1) CA2503570C (en)
CY (2) CY1111399T1 (en)
DE (1) DE60336334D1 (en)
DK (1) DK1559427T3 (en)
ES (1) ES2360353T3 (en)
FR (1) FR13C0032I2 (en)
HU (1) HUS1300027I1 (en)
IL (1) IL168121A (en)
LU (1) LU92218I2 (en)
MX (1) MXPA05004925A (en)
NL (1) NL300599I2 (en)
NO (2) NO334948B1 (en)
NZ (1) NZ539577A (en)
PL (1) PL211687B1 (en)
PT (1) PT1559427E (en)
RU (1) RU2321401C2 (en)
SI (1) SI1559427T1 (en)
WO (1) WO2004041276A1 (en)
ZA (1) ZA200503510B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (en) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the treatment of stress incontinence and / or mixed incontinence
SI2216021T1 (en) 2007-11-02 2013-01-31 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
WO2009081837A1 (en) 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for ameliorating lower urinary tract symptom
PE20091825A1 (en) * 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
TWI478712B (en) * 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
JP5553767B2 (en) * 2008-11-07 2014-07-16 大日本住友製薬株式会社 New and useful treatment for lower urinary tract symptoms
WO2010147830A2 (en) * 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
ES2665467T3 (en) 2010-03-29 2018-04-25 Astellas Pharma Inc. Modified Release Pharmaceutical Composition
US8877214B2 (en) * 2010-03-29 2014-11-04 Astellas Pharma Inc. Pharmaceutical composition for modified release
US9283210B2 (en) 2011-05-18 2016-03-15 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
WO2013147134A1 (en) 2012-03-30 2013-10-03 アステラス製薬株式会社 Mirabegron-containing pharmaceutical composition
SG11201501415RA (en) 2012-08-31 2015-05-28 Astellas Pharma Inc Orally administered medical composition
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (en) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 Synthesis method of mirabegron
CN103232368B (en) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 A kind of synthetic method of (R)-4-nitrophenethyl-(2-hydroxyl-2-styroyl)-t-butyl carbamate
CN103193658A (en) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 Synthesis method of (R)-2-p-nitrobenzene ethylamine-1-phenethyl alcohol and salt thereof
CN103232352B (en) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (R)-4-(2-(2-hydroxyl-2-phenylethylamine base) ethyl) anilino carboxylate
KR20160033220A (en) * 2013-07-23 2016-03-25 알러간, 인코포레이티드 Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
ITMI20131653A1 (en) * 2013-10-07 2015-04-08 Dipharma Francis Srl CRYSTALLINE FORMS OF AN ADRENERGIC AGONIST
RU2550968C1 (en) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Integrated method of treating female patients suffering from chronic recurrent cystitis and refractory overactive bladder
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN104016943A (en) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 Synthetic method of mirabegron
CN104016877B (en) * 2014-06-13 2017-02-15 南京海融制药有限公司 Acetylaniline compounds and application thereof in preparation of mirabegron
CN104230840A (en) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 Synthesis method of mirabegron
KR20240010751A (en) 2014-11-20 2024-01-24 세레니티 파마슈티컬즈 엘엘씨 Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
CN104496841B (en) * 2014-11-26 2017-01-25 南京工业大学 Method for synthesizing mirabegron intermediate
CN104744292A (en) * 2015-03-11 2015-07-01 南京工业大学 Preparation method of (R)-2-((4=ethylnitrobenzene) amino)-2-oxo-1-phenethyl acetate or derivate thereof
JP2018090490A (en) * 2015-03-31 2018-06-14 アステラス製薬株式会社 Mirabegron-containing pharmaceutical composition
JP6618736B2 (en) 2015-09-01 2019-12-11 沢井製薬株式会社 Mirabegron-containing tablet, method for producing mirabegron-containing preparation, and method for producing mirabegron-containing granulated product
CN106278909B (en) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 Post-treatment method of mirabegron intermediate
ES2717534T3 (en) 2017-02-14 2019-06-21 Tiefenbacher Alfred E Gmbh & Co Kg Prodrugs of Mirabegron
KR102051132B1 (en) * 2017-03-17 2019-12-02 주식회사 종근당 Pharmaceutical composition for controlled release comprising Mirabegron or its salts
KR101868438B1 (en) 2017-04-13 2018-06-20 (주) 성운파마코피아 Method for preparing amide derivatives
WO2018221291A1 (en) 2017-05-31 2018-12-06 Ｓｂｉファーマ株式会社 Prophylactic or therapeutic agent for hyperactive bladder
KR102398639B1 (en) 2017-06-20 2022-05-17 (주) 성운파마코피아 Salts of amide derivatives and method for preparing the same
WO2019013583A2 (en) 2017-07-14 2019-01-17 주식회사 대웅제약 Pharmaceutical preparation and preparation method therefor
KR101937713B1 (en) 2017-07-14 2019-01-14 주식회사 대웅제약 Pharmaceutical formulation and preparation method for the same
KR20200117091A (en) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) Prodrug compound of mirabegron and its medical use for treating or alleviating overactive bladder diseases
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (en) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 Preparation method of (R) -2-hydroxy-N- [2- (4-aminophenyl) ethyl ] -2-phenethylamine
KR20220081033A (en) 2020-12-08 2022-06-15 주식회사 한서켐 Manufacturing method of α-type crystalline Mirabegron
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420120A2 (en) 1989-09-28 1991-04-03 Hokuriku Pharmaceutical Co., Ltd. Optically active benzyl alcohol compound and pharmaceutical composition
WO1992018461A1 (en) 1991-04-12 1992-10-29 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives with anti-pollakiuria activity
WO1993015041A1 (en) 1992-02-03 1993-08-05 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities
JPH06293664A (en) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd New pharmaceutical use of beta3-adrenergic agent
WO1994025427A1 (en) 1993-04-26 1994-11-10 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
JPH07228543A (en) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd New pharmaceutical use of beta3-adrenalin agonist
WO1998007445A1 (en) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
WO1999020607A1 (en) 1997-10-17 1999-04-29 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
WO1999031045A1 (en) 1997-12-18 1999-06-24 Kissei Pharmaceutical Co., Ltd. Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
WO1999052856A1 (en) 1998-04-14 1999-10-21 Kissei Pharmaceutical Co., Ltd. 2-methylpropionic acid derivatives and medicinal compositions containing the same
WO2000002846A1 (en) 1998-07-08 2000-01-20 Kissei Pharmaceutical Co., Ltd. Phenoxyacetic acid derivatives and medicinal compositions containing the same
AU715216B2 (en) 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
US6204285B1 (en) 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
JP2001114736A (en) 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd 2-aminopropanol derivative
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
WO2001054728A1 (en) 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
WO2001062705A2 (en) 2000-02-28 2001-08-30 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
WO2002000622A2 (en) 2000-06-27 2002-01-03 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
US6630515B2 (en) 1997-08-28 2003-10-07 Afferon Corporation Urinary incontinence therapy
US6699860B2 (en) 2000-12-11 2004-03-02 Bayer Pharmaceuticals Corporation Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
US20050004190A1 (en) 2001-10-30 2005-01-06 Souichirou Kawazoe Alpha-form or beta-form crystal of acetanilide derivative
US20050014190A1 (en) 1999-02-12 2005-01-20 Marta Blumenfeld Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
US20080009538A1 (en) 2005-03-21 2008-01-10 Phil Skolnick Methods and compositions for the treatment of urinary incontinence

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420120A2 (en) 1989-09-28 1991-04-03 Hokuriku Pharmaceutical Co., Ltd. Optically active benzyl alcohol compound and pharmaceutical composition
WO1992018461A1 (en) 1991-04-12 1992-10-29 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives with anti-pollakiuria activity
WO1993015041A1 (en) 1992-02-03 1993-08-05 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities
JPH06293664A (en) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd New pharmaceutical use of beta3-adrenergic agent
WO1994025427A1 (en) 1993-04-26 1994-11-10 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
JPH07228543A (en) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd New pharmaceutical use of beta3-adrenalin agonist
AU715216B2 (en) 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
US6069176A (en) 1995-10-26 2000-05-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as β 3 agonists, process for producing the same, and intermediates in the production of the same
US6204285B1 (en) 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
WO1998007445A1 (en) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
AU731391B2 (en) 1996-08-19 2001-03-29 Kissei Pharmaceutical Co. Ltd. Drug for the prevention or treatment of pollakiuria and urinary incontinence
EP0958835A1 (en) 1996-08-19 1999-11-24 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
US6630515B2 (en) 1997-08-28 2003-10-07 Afferon Corporation Urinary incontinence therapy
US6346532B1 (en) * 1997-10-17 2002-02-12 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
EP1028111B1 (en) 1997-10-17 2004-05-12 Yamanouchi Pharmaceutical Co. Ltd. Amide derivatives or salts thereof
WO1999020607A1 (en) 1997-10-17 1999-04-29 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
WO1999031045A1 (en) 1997-12-18 1999-06-24 Kissei Pharmaceutical Co., Ltd. Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
US6353025B1 (en) 1997-12-18 2002-03-05 Kissei Pharmaceutical Co., Ltd. Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
WO1999052856A1 (en) 1998-04-14 1999-10-21 Kissei Pharmaceutical Co., Ltd. 2-methylpropionic acid derivatives and medicinal compositions containing the same
US6696489B1 (en) 1998-04-14 2004-02-24 Kissei Pharmaceutical Co., Ltd. 2-Methylpropionic acid derivatives and medicinal compositions containing the same
US6790865B2 (en) 1998-04-14 2004-09-14 Kissei Pharmaceutical Co., Ltd. 2-methylpropionic acid derivatives and pharmaceutical compositions comprising the same
US6538152B1 (en) 1998-07-08 2003-03-25 Kissei Pharmaceutical Co., Ltd. Phenoxyacetic acid derivatives and medicinal compositions containing the same
WO2000002846A1 (en) 1998-07-08 2000-01-20 Kissei Pharmaceutical Co., Ltd. Phenoxyacetic acid derivatives and medicinal compositions containing the same
US20050014190A1 (en) 1999-02-12 2005-01-20 Marta Blumenfeld Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
US6291491B1 (en) 1999-10-12 2001-09-18 Merck & Co., Inc. Amide derivatives as β 3 agonists
JP2001114736A (en) 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd 2-aminopropanol derivative
WO2001054728A1 (en) 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
EP1258253A1 (en) 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
US20030073846A1 (en) 2000-02-28 2003-04-17 Kiyoshi Taniguchi Aminoalcohol derivatives
WO2001062705A2 (en) 2000-02-28 2001-08-30 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
WO2002000622A2 (en) 2000-06-27 2002-01-03 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
US6699860B2 (en) 2000-12-11 2004-03-02 Bayer Pharmaceuticals Corporation Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
US20050004190A1 (en) 2001-10-30 2005-01-06 Souichirou Kawazoe Alpha-form or beta-form crystal of acetanilide derivative
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
US7982049B2 (en) 2001-10-30 2011-07-19 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
US20080009538A1 (en) 2005-03-21 2008-01-10 Phil Skolnick Methods and compositions for the treatment of urinary incontinence

Non-Patent Citations (205)

* Cited by examiner, † Cited by third party
Title
"International Preliminary Report on Patentability" dated May 26, 2004.
"Fujisawa synthesizes novel beta 3-agonist", The Prous Science Daily Essentials, May 3, 1996.
Abrams, P., et al., "The Standardisation of Terminology of Lower Urinary Tract Functions: Report from Standardisation Sub-committee of the International Continence Society" (2002), Neurorology and Urodynamics, 21: pp. 167-178.
Alfieri AB, et al. "Nlitric oxide synthases and cyclophosphamide-induced cystitis in rats" Naunyn-Schmiedeberg's Arch Pharmacol., vol. 363, pp. 353-357 (2001).
Andersen, J. T., et al. "Abnormalities of Bladder Innervation in Diabetes Mellitus", Urology, Apr. 1976, pp. 442-448, vol. 7, No. 4, XP002430159.
Anthony A., "Localization of the beta (beta) 3-adrenoceptor in the human gastrointestinal tracts: an immunohistochemical study" Aliment Pharmacol. Ther., vol. 12, pp. 519-525 (1998).
Anthony A., "Localization of the β (beta) 3-adrenoceptor in the human gastrointestinal tracts: an immunohistochemical study" Aliment Pharmacol. Ther., vol. 12, pp. 519-525 (1998).
Arch JRS, et al. (1984) "Atypical beta-adrenoceptors on brown adipocytes as a target for anti-obesity drugs" Nature (Lond) 309:163-165.
Arch JRS, et al. (1984) "Atypical β-adrenoceptors on brown adipocytes as a target for anti-obesity drugs" Nature (Lond) 309:163-165.
Arch, JRS, "β-3 and Atypical β-adrenoceptors", Medical Research Reviews, vol. 13, No. 6, 663-729 (1993).
Badawi et al. "Relaxant effects of b-adrenergic agonists on porcine and human detrusor muscle" Acta Physiol. Scand. 2005, 185, 151-159. *
Badone B., et al., "Synthesis of the Potent and Selective Atypical β-adrenergic Agonist SR59062A", Biorganic & Medicinal Chemistry Letters, vol. 4. No. 16, pp. 1921-1924 (1994).
Bardou M., et al. "In vitro inhibition of human colonic motility with SR 59119A and SR 59104A: evidence of a beta3-adrenoceptor-mediated effect" European Journal of Pharmacology. vol. 353, pp. 281-287 (1998).
Bardou M., et al. "In vitro inhibition of human colonic motility with SR 59119A and SR 59104A: evidence of a β3-adrenoceptor-mediated effect" European Journal of Pharmacology. vol. 353, pp. 281-287 (1998).
Berkowitz DE, et al. (1995) "Distribution of beta-3-adrenoceptor mRNA in human tissues" Eur. J. Pharmacol. 289:223-228.
Berkowitz DE, et al. (1995) "Distribution of β-3-adrenoceptor mRNA in human tissues" Eur. J. Pharmacol. 289:223-228.
Bianchetti, A., et al., "In vitro inhibition of intestinal motility by phenylethanolaminotetralines; evidence of atypical β-adrenoceptors in rat colour", Br. J. Pharmacol. (1990) 100, 831-839.
Blin, N. et al., "Structural and Conformational Features Determining Selective Signal Transduction in the beta3 Adrenergic Receptor", The American Society for Pharmacology and Experimental Therapeutics, (1993), vol. 44, pp. 1094-1104.
Blin, N. et al., "Structural and Conformational Features Determining Selective Signal Transduction in the β3 Adrenergic Receptor", The American Society for Pharmacology and Experimental Therapeutics, (1993), vol. 44, pp. 1094-1104.
Bloom, J., et al., Drugs of the Future, vol. 19, pp. 23-26 (1994).
Bylund, D., et al., "IV. International Union of Pharmacology Nomenclature of Adrenoceptors" Pharmacological Reviews, 1994, vol. 46, No. 2 p. 121-136.
Canadian Office Action issued in Application No. 2,503,570 dated Jun. 14, 2010.
Canadian Office Action issued in Application No. 2,503,570, dated Dec. 14, 2009.
Cecchi, R., et al., "Synthesis and β-adrenergic activity of atypical β3-adrenergic phenylethanolaminotetralin steroisomers", Eur. J. Med. Chem. (1994) 29, 259-267.
Cecil Texbook of Medicine. 2000, vol. 1, pp. 23-24, and 637-642. *
Cecil Textbook of Medicine, 2000, vol. 1, pp. 23-24 and 637-642.
Chamberlain PD, "The tissue distribution of the human beta3-adrenoceptor studied using a monoclonal antibody: Direct evidence of the beta3-adrenoceptor in human adipose tissue, atrium and skeletal muscle" International Journal of Obesity, vol. 23, pp. 1057-1065 (1999).
Chamberlain PD, "The tissue distribution of the human β3-adrenoceptor studied using a monoclonal antibody: Direct evidence of the β3-adrenoceptor in human adipose tissue, atrium and skeletal muscle" International Journal of Obesity, vol. 23, pp. 1057-1065 (1999).
Chen et al. ("Prevalence and Correlation of Urinary Incontinence and Overactive Bladder in Taiwanese Women", Neurourology and Urodynamics 2003, 22, 109-117, published on-line Feb. 10, 2003). *
Chinese Office Action dated Nov. 10, 2006.
Daniels DV, et al. (1999) "Functional pharmacological characterization of the muscarinic cholinoceptor-mediated inhibition of adenylyl cyclase in primary cultured human bladder detrusor smooth muscle cells" Life Sci. 64:590.
Dolan JA, et al. (1994) "beta-3 Adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines" J. Pharmacol. Exp. Ther. 269:1000-1006.
Dolan JA, et al. (1994) "β-3 Adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines" J. Pharmacol. Exp. Ther. 269:1000-1006.
Elliot et al. Mayo Clin Proc. Apr. 2001; 76:353-355. *
Elliot et al., Mayo Clin Proc. Apr. 2001; 76:353-355.
Emorine LJ, et al. (1989) "Molecular characterization of the human beta3-adrenergic receptor" Science (Wash DC) 245:1118-1121.
Emorine LJ, et al. (1989) "Molecular characterization of the human β3-adrenergic receptor" Science (Wash DC) 245:1118-1121.
Emorine, L., et al., "The human beta3-adrenoceptor: the search for a physiological function", TIPS vol. 15, pp. 3-7 (1994).
Emorine, L., et al., "The human β3-adrenoceptor: the search for a physiological function", TIPS vol. 15, pp. 3-7 (1994).
English translation of Written Demand for Trial (Mar. 24, 2011), filed in the Japanese Patent Office on Kissei Patent.
English translation of Written Oral Argument Statement Summary (Nov. 2, 2011), filed in the Japanese Patent Office on Kissei Patent.
English translation of Written Statement (1) (Sep. 30, 2011), filed in the Japanese Patent Office on Kissei Patent.
Evans BA, et al. "Alternative splicing generates two isoforms of the beta3-adrenoceptor which are differentially expressed in mouse tissues" British Journal of Pharmacology, vol. 127, pp. 1525-1531 (1999).
Evans BA, et al. "Alternative splicing generates two isoforms of the β3-adrenoceptor which are differentially expressed in mouse tissues" British Journal of Pharmacology, vol. 127, pp. 1525-1531 (1999).
Fabrizio DP, et al., "Functional Evidence for the Presence of β3-Adrenoceptors in the Guinea Pig Common Bile Duct and Colon" Pharmacology, vol. 51, pp. 288-297 (1995).
Forrest MJ, et al. "L-750355, a human beta3-adrenoceptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey" European Journal of Pharmacology, vol. 407, pp. 175-181 (2000).
Forrest MJ, et al. "L-750355, a human β3-adrenoceptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey" European Journal of Pharmacology, vol. 407, pp. 175-181 (2000).
Frazier EP, et al. (2005) "Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol?" J. Pharmacol. Exp. Ther. 313:260-267.
Fujimura T. et al. (1999) "Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle" J. Urol. 161:680-685.
Fujimura T. et al. (1999) "Expression and possible functional role of the β3-adrenoceptor in human and rat detrusor muscle" J. Urol. 161:680-685.
Furuno T. et al. (2006) "Enhanced inhibitory effects of beta-adrenoceptor agonist on cholinergic micturition contractions in muscarinic M2 receptor knockout mice" Neurourol. Urodyn. 25:590-591.
Galitzky J., et al. "Lipolytic effects of conventional beta3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta4-adrenoceptor" British Journal of Pharmacology, vol. 122, pp. 1244-1250 (1997).
Galitzky J., et al. "Lipolytic effects of conventional β3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative β4-adrenoceptor" British Journal of Pharmacology, vol. 122, pp. 1244-1250 (1997).
Granneman JG, et al. (1991) "Molecular cloning and expression of the rat beta3-adrenergic receptor" Mol. Pharmacol. 40:895-899.
Granneman JG, et al. (1991) "Molecular cloning and expression of the rat β3-adrenergic receptor" Mol. Pharmacol. 40:895-899.
Growcott UW, "Zeneca ZD7114 acts as an antagonist at β3-adrenoceptors in rat isolated ileum" British Journal of Pharmacology, vol. 110, pp. 1375-1380 (1993).
Guo-Ming Zhao, et al., "Advance on the Research on and Development of Beta-sub3-Adrenoceptor Agonists", Chinese Jornal of Medicinal Chemistry, Jun. 2001, pp. 177-181, vol. 11, No. 3, China Academic Journal Electronic Publishing House.
Hammond TG, et al. "Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey" Cardiocascular Research, vol. 49, pp. 741-750 (2001).
Hattori K., et al., "Asynnetric Synthesis of FR165914; Novel β-3-Adrenerigic Agent with a Benzocycloheptene Structure", Bioranic & Medicinal Chemistry Letters, vol. 5, No. 23, pp. 2821-2824 (1995).
Hegde SS, "Muscarinic receptors in the bladder: from basic research to therapeutics" British Journal of Pharmacology, vol. 147, pp. S80-S87 (2006).
Hegde SS, et al. (1997) "Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo" Br. J. Pharmacol. 120:1409-1418.
Hu B. et al. (2003) "Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes" Prog. Med. Chem. 41:167-194.
Hutchinson DS, et al. "Mouse beta3a- and beta3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways" British Journal of Pharmacology, vol. 135, pp. 1903-1914 (2002).
Hutchinson DS, et al. "Mouse β3a- and β3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways" British Journal of Pharmacology, vol. 135, pp. 1903-1914 (2002).
Igawa Y (2000) "Discussion: functional role of M1, M2, and M3 muscarinic receptors in overactive bladder" Urology 55:47-49.
Igawa Y. et al. (1998) "Possible beta3-adrenoceptor-mediated relaxation of the human detrusor" Acta. Physiol. Scand. 164:117-118.
Igawa Y. et al. (1998) "Possible β3-adrenoceptor-mediated relaxation of the human detrusor" Acta. Physiol. Scand. 164:117-118.
Igawa Y. et al. (1999) "Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle" Br. J. Pharmacol. 126:819-825.
Igawa Y. et al. (1999) "Functional and molecular biological evidence for a possible β3-adrenoceptor in the human detrusor muscle" Br. J. Pharmacol. 126:819-825.
Igawa Y., "Functional elucidation of beta-adrenoceptors in isolated human detrusor: Study using novel beta3-adrenoceptor agonist, KUC-7322" 9th annual meeting of Japanese voiding function association (2002).
Igawa Y., "Functional Investigation of beta adrenoreceptors in isolated human detrusor -using the novel selective beta-adrenoceptor agonist, KUC-7322", 9th annual meeting of Japanese voiding function association (2002).
Igawa Y., et al., "Pharmacological and Molecular-biological Elucidation of beta3-Adrenalin Receptor Function in the Human Detrusor Muscle" (1997) 85th annual meeting of Japanese Urological Association, p. 119.
Igawa Y., et al., "Functional and Molecular Biological Evidence of β3 Adrenoceptors in the Human Detrusor" The Journal of Urology, vol. 157, pp. Suppl. 175 (1997).
Igawa Y., et al., "Pharmacological and Molecular-biological Elucidation of β3-Adrenalin Receptor Function in the Human Detrusor Muscle" (1997) 85th annual meeting of Japanese Urological Association, p. 119.
Igawa, et al., "Relaxant Effects of Isoproterenol and Selective beta3-Adreenoceptor Agonists on Normal Low Complaint and Hyperreflexic Human Bladders" (2001), The Journal of Urology, vol. 165, pp. 240-244.
Igawa, et al., "Relaxant Effects of Isoproterenol and Selective β3-Adreenoceptor Agonists on Normal Low Complaint and Hyperreflexic Human Bladders" (2001), The Journal of Urology, vol. 165, pp. 240-244.
Igawa, Y., et al., "Functional and molecular biological evidence for a possible β3-adrenoceptor in the human detrusor muscle", British Journal of Pharmacology, vol. 126, pp. 819-825 (1999).
Ishiura Y., "Experimental Study of Voiding Dysfunction Induced by Cerebral Infraction in Rats" Nihon Hinyokigakkaishi, vol. 87, pp. 1221-1230 (1996).
Israeli Office Action dated Jul. 2, 2009.
J. Myslive{hacek over (c)}ek, J. {hacek over (R{acute over (i)}{hacek over (c)}n)}ý, S. Tu{hacek over (c)}ek, "Muscarinic and beta-adrenergic receptors in rat heart during hydrocortisone treatment" Life Sciences, vol. 64, Issues 6-7, pp. 355-596 (Jan. 8, 1999).
J. Myslive{hacek over (c)}ek, J. {hacek over (R{acute over (i)}{hacek over (c)}n)}ý, S. Tu{hacek over (c)}ek, "Muscarinic and β-adrenergic receptors in rat heart during hydrocortisone treatment" Life Sciences, vol. 64, Issues 6-7, pp. 355-596 (Jan. 8, 1999).
Jeffrey P. Weiss and Jerry G. Blaivas, "Nocturia", Journal of Urology, Jan. 2000, pp. 5-12, vol. 163, No. 1, XP005556162, ISSN: 0022-5347, American Urological Association, Inc.
Jens T. Andersen and William E. Bradley, "Abnormalities of Bladder Innervation in Diabetes Mellitus", Urology, Apr. 1976, pp. 442-448, vol. 7, No. 4, XP002430159.
Johnson M., "The beta-Adrenoceptor" American Journal of Respiratory and Critical Care Medicine, vol. 158, pp. S146-S153 (1998).
Johnson M., "The β-Adrenoceptor" American Journal of Respiratory and Critical Care Medicine, vol. 158, pp. S146-S153 (1998).
Kaidoh K. et al. (2002) "Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infracted rats" J. Urol. 168:1247-1252.
Kaidoh K. et al. (2002) "Effects of selective β2 and β3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infracted rats" J. Urol. 168:1247-1252.
Kato T., et al., "Synthesis of a New β3-Selective Adrenergic Receptor Agonist, FR149175" Nihon Yakugakukai 116th annual meeting (1996) p. 261.
Kawashima H., et al., "A novel human beta-3 adrenoceptor agonist AD-9677", Oct. 22, 1997-p. 1469 16th International Diabetes Federation Congress.
Korean Office Action issued in Application No. 10-2005-7008158, dated Nov. 21, 2009.
Krief S., et al. "Tissue Distribution of beta3-adrenergic Receptor mRNA in Man" Journal of Clinical Investigation, vol. 91, pp. 344-349 (1993).
Krief S., et al. "Tissue Distribution of β3-adrenergic Receptor mRNA in Man" Journal of Clinical Investigation, vol. 91, pp. 344-349 (1993).
Kubota Y., et al. "Inhibitory mechanism of BRL37344 on muscarinic receptor-mediated contractions of the rat urinary bladder smooth muscle" Naunyn-Schmiedeberg's Arch Pharmacol., vol. 366, pp. 198-203 (2002).
Kuratani, K., et al., "Enhancement of Gastric Mucosal Blood Flow by Beta-3 Adrenergic Agonists Prevents Indomethacin-Induced Antral Ulcer in the Rat", The Journal of Pharmacology and Experimental Therapeutics, (1994), vol. 270, No. 2, p. 559-565.
Langin D. et al. (1991) "Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species" Eur. J. Pharmacol. 199:291-301.
Langin D. et al. (1991) "Coexistence of three β-adrenoceptor subtypes in white fat cells of various mammalian species" Eur. J. Pharmacol. 199:291-301.
Larsen, J-J, "a and β-Adrenoceptors in the Detrusor Muscle and Bladder Base of the Pig and β-Adrenoceptors in the Detrusor Muscle of a Man". British Journal of Pharmacology, 1979, vol. 65, p. 215-222.
Lecci A., et al. "Pharmacological evaluation of the role of cyclooxygenase isoenzymes on the micturition reflex following cystitis in rats" British Journal of Pharmacology, vol. 130, pp. 331-338 (2000).
Levin, RM., al. "Identification of Receptor Subtypes in the Rabbit and Human Urinary Bladder by Selective Radio-Ligand Binding" The Journal of Urology, vol. 139, pp. 844-848 (1988).
Li JH, et al. "beta-Adrenoceptor Subtypes in the Detrusor of Guinea-Pig Urinary Bladder" Pharmacology, vol. 44, pp. 13-18 (1992).
Li JH, et al. "β-Adrenoceptor Subtypes in the Detrusor of Guinea-Pig Urinary Bladder" Pharmacology, vol. 44, pp. 13-18 (1992).
Liggett SB, (1992) "Functional properties of the rat and human beta3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells" Mol. Pharmacol. 42:634-637.
Liggett SB, (1992) "Functional properties of the rat and human β3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells" Mol. Pharmacol. 42:634-637.
Lipworth BJ, "Clinical pharmacology of β3-adrenoceptors" British Journal of Pharmacology, vol. 42, pp. 291-300 (1996).
Liu S., et al., "Effects of Atropine, Isoproterenol and Propranolol on the Rabbit Bladder Contraction Induced by Intra-Arterial Administration of Acetylcholine and ATP" The Journal of Urology, vol. 160, pp. 1863-1866 (1998).
Longhurst, P., et al., "Pharmacological characterization of beta-adrenoceptors mediating relaxation of the rat urinary bladder invitro" (1999), British Journal of Pharmacology, vol. 127, pp. 1744-1750.
Longhurst, P., et al., "Pharmacological characterization of β-adrenoceptors mediating relaxation of the rat urinary bladder invitro" (1999), British Journal of Pharmacology, vol. 127, pp. 1744-1750.
Manara, L., et al., "The phenylethanolaminotetralines: new selective agonists for atypical beta-adrenoceptpor", TIPS, vol. 11, pp. 229-230 (1990).
Manara, L., et al., "The phenylethanolaminotetralines: new selective agonists for atypical β-adrenoceptpor", TIPS, vol. 11, pp. 229-230 (1990).
Martin C. Michel, et al., "Effect of Diabetes on Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia", Journal of Urology, Jun. 2000, pp. 1725-1729, vol. 163, No. 6, XP005555510, ISSN: 0022-5347, American Urological Association, Inc.
Matteis RD, et al. "Immunohistochemical identification of the beta3-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine" International Journal of Obesity, vol. 26, pp. 1442-1450 (2002).
Matteis RD, et al. "Immunohistochemical identification of the β3-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine" International Journal of Obesity, vol. 26, pp. 1442-1450 (2002).
Michel et al. ("Effects of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia" Journal of Urology, 2000, 163, 1725-1729). *
Moniotte S., et al. "Real-time RT-PCR for the Detection of Beta-adrenoceptor Messenger RNAs in Small Human Endomyocardial Biopsies" J Mol. Cell Cardiol., vol. 33, pp. 2121-2133 (2001).
Morita T., et al., "The Effect of new beta-3 agonist, GC-332 to bladder function of anesthetized rats" (Japanese), Apr. 8-11, 1998, 86th annual meeting of the Japanese Urological Association, p. 48.
Morita T., et al., "The Presence and Function of beta3 Receptors in the Bladder and External Urethral Sphincter" (1997) 85th annual meeting of Japanese Urological Association, p. 119.
Morita T., et al., "The Presence and Function of β3 Receptors in the Bladder and External Urethral Sphincter" (1997) 85th annual meeting of Japanese Urological Association, p. 119.
Myrbetriq® Package Insert (Jun. 28, 2012).
Myslivecek, et al. "Distrubution of mRNA and binding sites of adrenocreptors and muscarinic receptors in the rat heart" Life Sciences (2005).
Nahmias C. et al. (1991) "Molecular characterization of the mouse beta3-adrenergic receptor: relationship with the atypical receptor of adipocytes" Embo (Eur. Mol. Biol. Organ) J. 10:3721-3727.
Nahmias C. et al. (1991) "Molecular characterization of the mouse β3-adrenergic receptor: relationship with the atypical receptor of adipocytes" Embo (Eur. Mol. Biol. Organ) J. 10:3721-3727.
Nathalie Blin, et al., "Structural And Conformational Features Determining Selective Signal Transduction In The β3-Adrenergic Receptor", The American Society for Pharmacology and Experimental Therapeutics, 1993, vol. 44, pp. 1094-1104.
Nergard, et al., "Characterization of the Adrenergic Beta-Receptor in the Urinary Bladder of Man and Car", Acta pharmacol. et toxicol. 1977, 40, 14-21.
Nergardh, A., et al., "Characterization of the Adrenergic Beta-Receptor in the Urinary Bladder of Man and Cat" Acta Pharmacol. et Toxicol. vol. 40, pp. 14-21 (1977).
Nomiya M. et al. (2003) "A quantitative analysis of mRNA expression of beta1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders" J. Urol. 170:649-653.
Nomiya M. et al. (2003) "A quantitative analysis of mRNA expression of β1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders" J. Urol. 170:649-653.
Nomiya M., "mRNA Expression level of alpha-1 and beta adrenoceptor (AR) subtypes and their roles in human bladders", p. 167, Apr. 20, 2002.
Notice of Filing and Particulars of Grounds of Invalidity regarding Kissei Australian Patent No. 731391, filed in the Federal Court of Australia, dated Mar. 2, 2010.
Osamu Yamaguchi, "β3-Anrenoceptors In Human Detrusor Muscle", Urology, 2002, 59 (Supplement 5A): 25-29.
Oshita M., et al. "Characterization of beta-adrenoceptors in urinary bladder: comparison between rat and rabbit" British Journal of Pharmacology, vol. 122, pp. 1720-1724 (1997).
Oshita M., et al. "Characterization of β-adrenoceptors in urinary bladder: comparison between rat and rabbit" British Journal of Pharmacology, vol. 122, pp. 1720-1724 (1997).
Ozawa H., et al. "Effect of Intravesical Nitric Oxide Therapy on Cyclophosphamide-Induced Cystitis" The Journal of Urology, vol. 162, pp. 2211-2216 (1999).
Park Y., "Existence of β3-Adrenoceptor and it's Functional Roll in the Human Ureter" The Journal of Urology, vol. 157, p. 77 (1997).
Park Y., et al., "The Presence of beta3-Adrenaline Receptors in the Human Ureter", Sep. 23, 1997 4th Japanese Neurogenic Bladder Association, p. 88.
Park Y., et al., "The Presence of β3-Adrenaline Receptors in the Human Ureter", Sep. 23, 1997 4th Japanese Neurogenic Bladder Association, p. 88.
Park, Y., et al., "β-Adrenaline Receptor Subtypes in the Human Ureter" (1997) 85th annual meeting of Japanese Urological Association, The Japanese Journal of Urology, vol. 88, p. 152 (216) (1997).
Paul Abrams et al., "The Standardisation of Terminology in Lower Urinary Tract Function: Report from the Standardisation Sub-Committee of the International Continence Society," Urology, vol. 61, pp. 37-49 (2003).
Paul Abrams et al., "The Standardisation of Terminology of Lower Urinary Tract Functions: Report from the Standardisation Sub-committee of the International Continence Society" (2002), Neurourology and Urodynamics, 21: pp. 167-178.
Penelope A. Longhurst et al., "Pharmacological characterization of β-adrenoceptors mediating relaxation of the rat urinary bladder in vitro" (1999), British Journal of Pharmacology, vol. 127, pp. 1744-1750.
Polish Office Action issued in Application No. P-376771 dated Mar. 31, 2011.
Ralph Howe, "β-Adrenergic Agonists", Drugs of the Future, 1993, vol. 18, No. 6, pp. 529-549.
Ralph-Howe, "beta-Adrenergic Agonists", Drugs of the Future, (1993), vol. 18, No. 6, pp. 529-549.
Ralph-Howe, "β-Adrenergic Agonists", Drugs of the Future, (1993), vol. 18, No. 6, pp. 529-549.
Sacco, E., et al., "Mirabegron: a review of recent data and its prospects in the management of overactive bladder", Therapeutic Advances in Urology, 2012) 4(6) 315-324.
Seguchi H, et al. "Expression of beta 3-Adrenoceptors in Rat Detrusor Smooth Muscle" The Journal of Urology, vol. 159, pp. 2197-2201 (1998).
Seguchi H., et al., "β3-Adrenaline Receptor Expression in Rat Bladder" (1997) 85th annual meeting of Japanese Urological Association, The Japanese Journal of Urology, vol. 88, p. 230 (294) (1997).
Strosberg, D., et al. "Function and regulation of the beta3-Adrenoceptpor" TIPS, vol. 17 pp. 373-381 (1996).
Strosberg, D., et al. "Function and regulation of the β3-Adrenoceptpor" TIPS, vol. 17 pp. 373-381 (1996).
Supplementary European Search Report in European Application No. 03770134.9 dated Apr. 19, 2007.
Takashi Morita, et al., "Function and Distribution of Beta-sub3-Adrenoceptors in Rat, Rabbit and Human Urinary Bladder and External Urethral Sphincter", J. Smooth Muscle Res., 2000, pp. 21-32, vol. 36.
Takashi Morita, et al., The Japanese Journal of Urology, 88 (2), p. 119, (p. 183) 1997.
Takashi Mortia., et al., The Japanese Journal of Urology, 88 (2), p. 119, (p. 183) 1997.
Takashi, Mortia., et al., "Function and Distribution of Beta-sub3-Adrenoceptors in Rat, Rabbit and Human Urinary Bladder and External Urethral Sphincter", J. Smooth Muscle Res., 2000 pp. 21-32, vol. 36.
Takasu T. et al. (2007) "Effect of (R)-2-(2-Aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2 phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective beta3-Adrenoceptor Agonist, on Bladder Function," J. Pharmacol. Exp. Ther. 321(2):642-647.
Takasu T. et al. (2007) "Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2 phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective β3-Adrenoceptor Agonist, on Bladder Function," J. Pharmacol. Exp. Ther. 321(2):642-647.
Takeda H. et al. (2002) "Effects of beta3-adrenoceptor stimulation on prostaglandin E2-induced bladder hyperactivity and on the cardiovascular system in conscious rats" Neurourol. Urodyn. 21:558-565.
Takeda H. et al. (2002) "Effects of β3-adrenoceptor stimulation on prostaglandin E2-induced bladder hyperactivity and on the cardiovascular system in conscious rats" Neurourol. Urodyn. 21:558-565.
Takeda H., et al. "Functional Characterization of beta-Adrenoceptor Subtypes in the Canine and Rat Lower Urinary Tract" The Journal of Urology, vol. 170, pp. 654-658 (2003).
Takeda H., et al. "Role of the beta3-Adrenoceptor in Urine Storage in the Rat: Comparison between the Selective beta3-Adrenoceptor Agonist, CL316.243, and Various Smooth Muscle Relaxants" The Journal of Pharmacology and Experimental Therapeutics, vol. 293, pp. 939-945 (2000).
Takeda H., et al. "Functional Characterization of β-Adrenoceptor Subtypes in the Canine and Rat Lower Urinary Tract" The Journal of Urology, vol. 170, pp. 654-658 (2003).
Takeda H., et al. "Role of the β3-Adrenoceptor in Urine Storage in the Rat: Comparison between the Selective β3-Adrenoceptor Agonist, CL316.243, and Various Smooth Muscle Relaxants" The Journal of Pharmacology and Experimental Therapeutics, vol. 293, pp. 939-945 (2000).
Takeda H., et al., "Effects of beta-Adrenaline Receptor Agonists on the Intravesical Pressure in Anesthetized Rats" Apr. 8-11, 1998, 86th annual meeting of the Japanese Urological Association, p. 49.
Takeda H., et al., "Effects of β-Adrenaline Receptor Agonists on the Intravesical Pressure in Anesthetized Rats" Apr. 8-11, 1998, 86th annual meeting of the Japanese Urological Association, p. 49.
Takeda M. et al. (1999) "Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods" J. Pharmacol. Exp. Ther. 288:1367-1373.
Takeda M. et al. (1999) "Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods" J. Pharmacol. Exp. Ther. 288:1367-1373.
Takeda M., "The Role of Autonomic Receptors and Neuroactive Substances in the Lower Urinary Tract Smooth Muscle Tissue" (Japanese), Apr. 8-11, 1998, 86th annual meeting of the Japanese Urological Association, pp. 19-20.
Takeda M., "Adrenergic β1, β2, and β3 Receptor Subtypes in the Detrusor of Human Urinary Bladder"The Journal of Urology, vol. 157, pp. Suppl. 82 (1997) and Apr. 13, 1997 92nd annual meeting of American Urological Association) vol. 157.
Takeda M., et al., "beta3 Receptor in the Human Bladder Detrusor Muscle-Molecular-biological and Pharmacological Study", Sep. 23, 1997 4th Japanese Neurogenic Bladder Association.
Takeda M., et al., "Expression of β-Adrenergic Receptor Subtype mRNA and β-Adrenergic Receptor Kinase mRNA in the Humanh Bladder Detrusor Muscle—The Role of β-Adrenergic Receptor in Urine Collection and the Possibility of the Presence of a Desensitization Mechanism" (1997) 85th annual meeting of Japanese Urological Association, The Japanese Journal of Urology, vol. 88, p. 119 (183) (1997).
Takeda M., et al., "β3 Receptor in the Human Bladder Detrusor Muscle-Molecular-biological and Pharmacological Study", Sep. 23, 1997 4th Japanese Neurogenic Bladder Association.
Tatsuya Maruyama, "Discovery of YM178 (Mirabegron) as a Potent and Selective β3 Adrenoceptor Agonist for the Treatment of Overactive Bladder", Drug Discovery Research, Astellas Pharma Inc. (2012).
Toyama M., et al., "beta3-Adrenaline Receptor Subtype in Rabbit and Dog Ureteral Smooth Muscle", Sep. 23, 1997 4th Japanese Neurogenic Bladder Association, p. 87.
Toyama M., et al., "Species Differences in β-Adrenaline Receptor Subtypes in the Ureteral Smooth Muscle" (1997) 85th annual meeting of Japanese Urological Association, The Japanese Journal of Urology, vol. 88, p. 235 (299) (1997).
Toyama M., et al., "β3-Adrenaline Receptor Subtype in Rabbit and Dog Ureteral Smooth Muscle", Sep. 23, 1997 4th Japanese Neurogenic Bladder Association, p. 87.
Wagner et al. Health-Related consequences of overactive bladder. The American Journal of Managed Care. Dec. 2002; 8(19, Sup):S598-S607. *
Wagner et al., "Health-Related consequences of overactive bladder", The American Journal of Managed Care, Dec. (2002) 8(19, Sup):S598-S607.
Weiss, J.P., et al., "Noctuira", Journal of Urology,Jan. 2000, pp. 5-12, vol. 163,No. 1, XP005556162, ISSN: 0022-5347, American Urological Association, Inc.
Weyer C., et al. "Increase in Insulin Action and Fat Oxidation After Treatment With CL 316,243, a Highly Selective beta3-Adrenoceptor Agonist in Humans" Diabetes, vol. 47, pp. 1555-1561 (1998).
Weyer C., et al. "Increase in Insulin Action and Fat Oxidation After Treatment With CL 316,243, a Highly Selective β3-Adrenoceptor Agonist in Humans" Diabetes, vol. 47, pp. 1555-1561 (1998).
Wilson S. et al. (1996) "Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay" J. Pharmacol. Exp. Ther. 279:214-221.
Woods M. et al. (2001) "Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat" J. Urol. 166:1142-1147.
Woods M. et al. (2001) "Efficacy of the β3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat" J. Urol. 166:1142-1147.
World Health Organization, Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, WHO (1999).
World Health Organization, Definition, Diagnosis and Classification of Diabetes Mellitus and its WHO/IDF Consultation (2006).
Yamaguchi O., "Pharmacological of Treatment of Overactive Bladder" Pharma Medica, vol. 24, pp. 37-40 (2006).
Yamaguchi O., et al., "Evaluation of mRNAs Encoding Muscarinic Receptor Subtypes in Human Detrusor Muscle" The Journal of Urology, vol. 156, pp. 1208-1213 (1996).
Yamaguchi, O., "beta3-Anrenoceptors inHuman Detrusor Muscle", Urology, 2002, 59 (Supplement 5A): 25-29.
Yamaguchi, O., "β3-Anrenoceptors inHuman Detrusor Muscle", Urology, 2002, 59 (Supplement 5A): 25-29.
Yamamoto Y., et al. "The Effects of beta-Adrenoceptor Agonists on KCI-induced Rhythmic Contraction in the Ureter of Guinea Pig" Journal of Smooth Muscle Research, vol. 36, pp. 13-19 (2000).
Yamamoto Y., et al. "The Effects of β-Adrenoceptor Agonists on KCI-induced Rhythmic Contraction in the Ureter of Guinea Pig" Journal of Smooth Muscle Research, vol. 36, pp. 13-19 (2000).
Yamasaki Y., et al., "β-Adrenalin Receptor Subtype in the Rabbit, Rat, and Dog Bladder Detrusor Muscle" (1997) 85th annual meeting of Japanese Urological Association, The Japanese Journal of Urology, vol. 88, p. 119 (183) (1997).
Yamazaki Y. et al. (1998) "Species differences in the distribution of beta3-adrenoceptor subtypes in bladder smooth muscle" Br. J. Pharmacol. 124:593-599.
Yamazaki Y. et al. (1998) "Species differences in the distribution of β3-adrenoceptor subtypes in bladder smooth muscle" Br. J. Pharmacol. 124:593-599.
Yamazaki Y., et al., "Characterization of KUC-7483 and its active metabolite KUC-7322, a selective beta-3 adrenoceptor agonist on bladder function in rats" 32nd Annual Meeting of International Continence Society, p. 95 (2002).
Yanagisawa T., et al., "Selectivity and Potency of Agonists for the Three Subtypes of Cloned Human β-adrenoceptors Expressed in Chinese Hamster Ovary Cells", Tohoku J Exp. Med., vol. 192, pp. 181-193 (2000).
Yarker Ye et al. (1995) "Oxybuthynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability" Drugs & Aging 6:243-262.
Yasuhiko Igawa et al., "Relaxant Effects of Isoproterenol and Selective β-3Adreenoceptor Agonists On Normal Low Compliant and Hyperreflexic Human Bladders" (2001), The Journal of Urology, vol. 165, pp. 240-244.
Yasuhiko Igawa, et al., The Japanese Journal of Urology, 88 (2), p. 119, (p. 183) 1997.
Yasuhiko Igawa., et al., The Japanese Journal of Urology, 88 (2) p. 119 (p. 183) 1997.
Yono M., et al. "Pharmacological effects of tolterodine on human isolated urinary bladder" European Journal of Pharmacology, vol. 368, pp. 223-230 (1999).
Yoshida M., et al. "Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles" Expermental Gerontology, vol. 36, pp. 99-109 (2001).
You-Tang S., et al. "Differences in beta3-Adrenergic Receptor Cardiovascular Regulation in Conscious Primates, Rats and Dogs" The Journal of Pharmacology and Experimental Therapeutics, vol. 278, pp. 1435-1443 (1996).
You-Tang S., et al. "Peripheral Vascular Effects of Beta-3 Adrenergic Receptor Stimulation in Conscious Dogs" The Journal of Pharmacology and Experimental Therapeutics, vol. 268, pp. 466-473 (1994).
You-Tang S., et al. "Differences in β3-Adrenergic Receptor Cardiovascular Regulation in Conscious Primates, Rats and Dogs" The Journal of Pharmacology and Experimental Therapeutics, vol. 278, pp. 1435-1443 (1996).
Zhao, Guo-Ming et al., "Advance on the Research on and Development of Beta-sub3-Adrenoceptor Agonists", Chinese Journal of Medicinal Chemistry, Jun. 2001, pp. 177-181, vol. 11, No. 3, China Academic Journal Electronic Publishing House.

Also Published As

Publication number Publication date
FR13C0032I2 (en) 2014-03-07
EP1559427B1 (en) 2011-03-09
HUS1300027I1 (en) 2016-08-29
DE60336334D1 (en) 2011-04-21
BR0316080A (en) 2005-09-27
KR100967070B1 (en) 2010-07-01
US20060115540A1 (en) 2006-06-01
PL211687B1 (en) 2012-06-29
IL168121A (en) 2011-12-29
ZA200503510B (en) 2006-12-27
AU2003284700A1 (en) 2004-06-07
NO20052691D0 (en) 2005-06-06
NO334948B1 (en) 2014-08-04
AU2003284700B2 (en) 2009-05-28
JP3815496B2 (en) 2006-08-30
RU2005117367A (en) 2006-01-20
PL376771A1 (en) 2006-01-09
ATE500827T1 (en) 2011-03-15
CA2503570A1 (en) 2004-05-21
NO2015001I2 (en) 2015-01-26
NO2015001I1 (en) 2015-01-19
CY1111399T1 (en) 2015-08-05
KR20050072809A (en) 2005-07-12
FR13C0032I1 (en) 2013-08-09
DK1559427T3 (en) 2011-04-26
CY2013023I2 (en) 2015-10-07
BE2013C040I2 (en) 2023-03-07
MXPA05004925A (en) 2005-08-18
US7750029B2 (en) 2010-07-06
NL300599I2 (en) 2017-01-03
US20110230530A1 (en) 2011-09-22
WO2004041276A1 (en) 2004-05-21
SI1559427T1 (en) 2011-06-30
CN100406011C (en) 2008-07-30
LU92218I2 (en) 2014-01-07
PT1559427E (en) 2011-05-27
CA2503570C (en) 2011-04-19
ES2360353T3 (en) 2011-06-03
US8835474B2 (en) 2014-09-16
EP1559427A4 (en) 2007-05-30
RU2321401C2 (en) 2008-04-10
US20090093529A1 (en) 2009-04-09
CY2013023I1 (en) 2015-10-07
LU92218I9 (en) 2019-01-17
NZ539577A (en) 2007-06-29
JPWO2004041276A1 (en) 2006-03-02
EP1559427A1 (en) 2005-08-03
NO20052691L (en) 2005-07-15
CN1711085A (en) 2005-12-21

Similar Documents

Publication Publication Date Title
USRE44872E1 (en) Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US20090105298A1 (en) Pharmaceutical composition for therapy of interstitial cystitis
US8481577B2 (en) Amide thiazole derivative, preparation method and uses thereof
JPWO2004014428A1 (en) Treatment for bowel disease and visceral pain
SK12162002A3 (en) 8,8a-Dihydro-indeno[1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents
US20090093415A1 (en) Therapeutic agent for irritable bowel syndrome
JPH10130144A (en) Usage of nonpeptide bradykinin antagonist for preparation of medicine for treatment and prevention of alzheimer disease
US6638951B1 (en) Benzamide derivatives and drugs containing the same
AU2021288679A1 (en) Methods for treating or preventing chronic kidney disease
US20090197916A1 (en) Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
EP1393731A1 (en) Novel use of arylethenesulfonamide derivative
JP4598674B2 (en) Schizophrenia treatment
WO2007123126A1 (en) Agent for improving decreased exercise tolerance in chronic heart failure
KR20040106345A (en) Oral therapeutic or preventive drugs for pollakiuria and urinary incontinence or oral sleep inducers, containing tropolone derivatives
JP2000290198A (en) Depressant against nasal cavity resistant increase or the like

Legal Events

Date Code Title Description
PTEF Application for a patent term extension

Free format text: PRODUCT NAME: MYRBETRIQ (MIRABEGRON); REQUESTED FOR 515 DAYS; WAS 7,750,029

Filing date: 20120823

Expiry date: 20231018

PTER Rejection of a request for patent term extension (for eg. ineligible, dismissal, withdrawal, etc)

Free format text: PRODUCT NAME: MYRBETRIQ (MIRABEGRON)

Filing date: 20120823

Expiry date: 20231018

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552)

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12